公开(公告)号：US20170007119A1

公开(公告)日：2017-01-12

申请号：US15117995

申请日：2015-02-10

Applicant: BRIEN HOLDEN VISION DIAGNOSTICS INC.

Inventor： Tom N Cornsweet ,  Paul Peterson ,  Brad Bower

IPC: A61B3/113 ,  A61B5/00 ,  A61B3/00 ,  A61B3/12 ,  A61B3/14 ,  A61B3/11

CPC classification number: A61B3/113 ,  A61B3/0025 ,  A61B3/0058 ,  A61B3/0091 ,  A61B3/112 ,  A61B3/1216 ,  A61B3/14 ,  A61B5/4064

Abstract: A device for monitoring eye movement and pupil response that comprises a first optical pathway for displaying one or more images to the eyes of a patient and a second optical pathway for obtaining images of the eyes of a patient. The device further comprises at least one screen for displaying an image to the left eye of the patient which is not visible to the right eye of the patient and for displaying an image to the right eye of the patient which is not visible to the left eye of the patient; a first camera for capturing images of the left eye of the patient; and a second camera for capturing images of the right eye of the patient at substantially the same time as the first camera is capturing images of the left eye of the patient. The device also comprises at least one IR light source for illuminating the eyes of the patient; and a processor for processing the obtained images and measuring pupil response and/or eye movements.

Abstract translation: 一种用于监测眼睛运动和瞳孔响应的装置，包括用于向患者的眼睛显示一个或多个图像的第一光学路径和用于获得患者眼睛的图像的第二光学路径。 该装置还包括至少一个屏幕，用于向患者的左眼显示图像，其对于患者的右眼不可见，并且用于向左眼不可见的患者的右眼显示图像 的病人 用于捕获患者左眼的图像的第一相机; 以及第二相机，用于在与第一相机正在捕获患者的左眼的图像的基本同时捕获患者的右眼的图像。 该装置还包括用于照亮患者眼睛的至少一个IR光源; 以及用于处理所获得的图像并测量瞳孔响应和/或眼睛运动的处理器。

公开(公告)号：US20230313264A1

公开(公告)日：2023-10-05

申请号：US18011545

申请日：2021-07-01

Applicant: VISION DIAGNOSTICS, INC.

Inventor： JERRY W. DENNEY

IPC: C12Q1/42

CPC classification number: C12Q1/42

Abstract: A kit comprising two reagents for conducting two different Assays to measure a zinc-activated enzyme in a bodily fluid. The assay results are utilized to obtain a relative zinc-activated enzyme activity value that can be correlated to tissue zinc levels. A more specific embodiment utilizes two paired reagents for conducting an A Assay and a B Assay that measure different alkaline phosphatase (ALP) activities in a urine sample to obtain a Relative Renal Alkaline Phosphatase Activity (RRAPA) value. The RRAPA value can be correlated to zinc levels in renal tissue.

公开(公告)号：US20220128540A1

公开(公告)日：2022-04-28

申请号：US17570413

申请日：2022-01-07

Applicant: VISION DIAGNOSTICS, INC.

Inventor： JERRY W. DENNEY

IPC: G01N33/487 ,  G01N33/537 ,  G01N33/52 ,  G01N33/539 ,  G01N33/493

Abstract: Assays and methods for verifying the validity of a urine sample submitted for Drugs of Abuse (DOA) testing. Embodiments include a SUD Diagnostic Panel that includes six assays: specific gravity index assay, long-duration counterfeit urine assay, short-duration counterfeit urine assay, oxidant history assay, pH assay, and creatinine assay. The SUD Diagnostic Panel detects twelve principle classes of adulteration. Detection of adulteration of one or more urine samples from a patient indicates an attempt to subvert test results and provides an objective indication in one instance and an object diagnosis in another instance of SUD.

公开(公告)号：US09936869B2

公开(公告)日：2018-04-10

申请号：US15409299

申请日：2017-01-18

Applicant: Brien Holden Vision Diagnostics, Inc.

Inventor： Tom N. Cornsweet ,  Paul R. Peterson

IPC: A61B3/14 ,  A61B3/00 ,  A61B3/10 ,  A61B3/12 ,  A61B3/103

CPC classification number: A61B3/12 ,  A61B3/0008 ,  A61B3/0025 ,  A61B3/103 ,  A61B3/14 ,  G02B7/09 ,  G02B27/0068

Abstract: An ocular fundus camera system and an associated methodology. The system includes (a) an image sensor disposed along a fundus-image reflection path adjacent that path's downstream end, and in optical communication with light carried in this path, (b) an aperture centered on the reflection path's long axis, operatively associated with, and stationary with respect to, the sensor at a location which is upstream from the sensor, and (c), for accomplishing (1) precision fundus-image focusing on the sensor, and additionally (2) autorefraction, optical, light-content shifting structure, operable selectively for producing, within that portion of the reflection path which is disposed downstream from the shifting structure, relative trans-axial displacement solely of any non-collimated light carried in that portion of the main path which is disposed upstream from the shifting structure.

公开(公告)号：US11460409B1

公开(公告)日：2022-10-04

申请号：US15961003

申请日：2018-04-24

Applicant: Vision Diagnostics, Inc.

Inventor： Jerry W. Denney

IPC: G01N21/78 ,  G01N33/493 ,  C12Q1/42 ,  G01N21/77 ,  G01N33/487 ,  G01N21/75

Abstract: The problem of detecting whether a urine sample is true human urine or a counterfeit urine product is solved by the use of reagent systems that detect two markers normally present in human urine. The markers acid phosphatase and alkaline phosphatase catalyze the substrates thymolphthalein monophosphate and p-nitrophenol phosphate, respectively. These substrates are formulated as spot tests on a dip stick or as reagents for use in automated chemical analyzers. The presence of the markers can be qualitatively detected by color-changes in the sample, formed by the pH-specific chromogens that result from catalysis of the substrates with the markers. The control reagent can further indicate whether a counterfeit urine product contains one or both of the chromogens.

公开(公告)号：US11493498B2

公开(公告)日：2022-11-08

申请号：US17570413

申请日：2022-01-07

Applicant: VISION DIAGNOSTICS, INC.

Inventor： Jerry W. Denney

IPC: G01N33/487 ,  G01N33/493 ,  G01N33/52 ,  G01N33/537 ,  G01N33/539

Abstract: Assays and methods for verifying the validity of a urine sample submitted for Drugs of Abuse (DOA) testing. Embodiments include a SUD Diagnostic Panel that includes six assays: specific gravity index assay, long-duration counterfeit urine assay, short-duration counterfeit urine assay, oxidant history assay, pH assay, and creatinine assay. The SUD Diagnostic Panel detects twelve principle classes of adulteration. Detection of adulteration of one or more urine samples from a patient indicates an attempt to subvert test results and provides an objective indication in one instance and an object diagnosis in another instance of SUD.

公开(公告)号：US20190025284A1

公开(公告)日：2019-01-24

申请号：US16139802

申请日：2018-09-24

Applicant: Vision Diagnostics, Inc.

Inventor： Jerry W. Denney

IPC: G01N33/493 ,  G01N21/31 ,  G01N21/78

CPC classification number: G01N33/493 ,  G01N21/3103 ,  G01N21/78 ,  Y10T436/148888 ,  Y10T436/16

Abstract: The problem of confirming the presence of an adulterant in a urine sample is solved by the use of a reagent capable of reacting with uric acid and non-urate markers in a urine sample. In one embodiment, a phosphotungtate reagent is used to react with the urine sample to create a blue coloration in the presence of uric acid or uric acid equivalents. A reduction or elimination of the blue coloration, resulting in a reduction in the light absorbance, of the urine sample can be used as an indicator of the historical presence of an adulterant. An Oxidant History test can also be generated using the phosphostungtate reagent, wherein the light absorbance resulting from the blue coloration is measured over time, with a measured reduction in the absorbance being an indication that an adulterant is or has been present in the urine sample and is oxidizing the uric acid and non-urate markers over time.